Home » Authors » Anette Breindl

Articles by Anette Breindl

First Ebola/Marburg Vaccine Successfully Jumps Species

June 10, 2005

By Anette Breindl

Cell-Cycle Inhibitors Might Be Able To Treat Brain Injury

June 8, 2005

By Anette Breindl

Cell-Cycle Inhibitors Might Be Able To Treat Brain Injury

June 8, 2005

By Anette Breindl

After Clinical Setback, Glucose Synthesis Inhibitor Moves On

June 6, 2005

By Anette Breindl

After Clinical Setback, Glucose Synthesis Inhibitor Moves On

June 6, 2005

By Anette Breindl

New Anti-Angiogenesis Theory: How To Give Tumors A Stroke

June 3, 2005

By Anette Breindl

New Anti-Angiogenesis Theory: How To Give Tumors A Stroke

June 3, 2005

By Anette Breindl

Even After Injury, No Neurons From Blood Stem Cells Found

June 1, 2005

By Anette Breindl

Even After Injury, No Neurons From Blood Stem Cells Found

June 1, 2005

By Anette Breindl

In Avian Flu, To Kill Or Not To Kill? Perhaps Vaccinate

May 31, 2005

By Anette Breindl

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 8, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
AI drives financings, approvals for APAC med-tech in 2024
BioWorld MedTech
AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific countries played to individual strengths to maximize AI’s applications in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.